Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

Presentation TCT 2019

LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Presenter: Kenneth Ouriel

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

Presentation TCT 2015

Extended Follow-up From LEVANT 2: Two-Year Follow-up and Subgroup Analyses

Presenter: William A. Gray, Peter A. Schneider, Andrej Schmidt

October 12, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2014

Randomized Controlled Trials I: Extended Follow-Up From LEVANT 2 - Analysis of one year Follow-up and Beyond

Presenter: Kenneth Rosenfield, Thomas Zeller, Raghu Kolluri

September 15, 2014

Presentation TCT 2013

LEVANT 2

Presenter: D. Christopher Metzger

October 31, 2013

Presentation TCT 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presenter: Kenneth Rosenfield

October 30, 2013

News Conference News TCT 2013

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

October 30, 2013

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Kenneth Ouriel About LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

September 26, 2019

Advertisement

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Extended Follow-up From LEVANT 2: Two-Year Follow-up and Subgroup Analyses

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Randomized Controlled Trials I: Extended Follow-Up From LEVANT 2 - Analysis of one year Follow-up and Beyond

LEVANT 2

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

Dr. C. Michael Gibson Talks With Dr. Kenneth Ouriel About LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content